�ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that its disease-directed Phase 2 clinical trial in patients with advanced prostate crab randomized to treatment with either IMC-A12 or IMC-1121B plus mitoxantrone and deltasone has commenced patient enrollment. IMC-A12 and IMC-1121B ar two therapeutic candidates in ImClone's proprietary receptor-targeted antibody pipeline. IMC-A12 is ImClone's fully human, IgG1 anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody and IMC-1121B is its fully human, IgG1 anti-vascular growth constituent receptor-2 (VEGFR-2) monoclonal antibody.
This multicenter, randomized open-label Phase 2 single-arm subject is enrolling patients with metastatic androgen-independent prostate cancer who have developed disease progression during or inside 60 years of receiving docetaxel-based chemotherapy or demonstrated intolerance to docetaxel-based therapy. A total of 132 patients ar expected to be enrolled at assorted centers, including those that participate in the Department of Defense's Prostate Cancer Consortium. This Phase 2 study is designed to evaluate the efficacy and safety of both IMC-A12 and IMC-1121B combined with mitoxantrone and prednisone. IMC-A12 and IMC-1121B are administered weekly, whereas mitoxantrone is administered every three weeks with oral daily prednisone.
"We are very proud of about beginning another disease-directed, proof-of-concept trial which expeditiously evaluates deuce of our pipeline antibodies with distinct mechanisms of action, til now each with potential applicability in the treatment of prostate cancer based on preclinical investigations performed by ImClone and academic collaborators," said Eric K. Rowinsky, M.D., Chief Medical Officer and Executive Vice President of ImClone. "The results of whatsoever one of the work arms, or even both, in concurrence with those of former ongoing clinical and preclinical studies, may serve as platforms for subsequent registration directed activity in several early- and advanced-stage prostate cancer settings."
IMC-A12 is a in full human IgG1 monoclonal antibody designed to specifically fair game the human IGF-1R, thereby inhibiting certain ligands known as IGFs 1 and 2 from binding to and activating the receptor. This action blocks a signaling pathway that enhances tumor cell proliferation and survival. In 2007, ImClone completed registration into deuce Phase 1 studies of IMC-A12 which demonstrated favorable safety and pharmacokinetic profiles, as advantageously as preliminary evidence of antitumor activity as a single agent when administered either weekly or every two weeks. In gain to this Phase 2 study announced today, Phase 2 studies of IMC-A12 in adult and adolescent patients with soft tissue paper sarcoma, untreated advanced prostate, pancreatic, colorectal, liver, and head and neck cancers, as well as a series of Phase 1/2 studies in pediatric malignancies and another evaluating the combination of IMC-A12 and temsirolimus, have begun to enroll patients.
IMC-1121B is a fully human IgG1 monoclonal antibody designed to bind to the extracellular domain of VEGFR-2 found on tumour vasculature, thereby inhibiting sure ligands known as vascular endothelial growth factors from binding to and activating the sensory receptor. This action mechanism blocks a signaling nerve tract key to new blood vessel geological formation in growing tumors, which has been shown to starve tumors of their nutrient supply and resultant in meaning tumor increase inhibition in pre-clinical models. In increase to this Phase 2 study announced today, disease-directed studies of IMC-1121B in patients with advanced malignant melanoma, liver and renal cancers have begun to enter patients, and additional Phase 2 and 3 evaluations are in various stages of development. In April 2008, ImClone announced an agreement with the Food and Drug Administration on a Special Protocol Assessment for a Phase 3 study of IMC-1121B in women with metastatic titty cancer, which recently commenced.
About ImClone Systems
ImClone Systems Incorporated is a fully integrated global biopharmaceutical company committed to advancing oncology guardianship by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. The Company's inquiry and development programs include growth cistron blockers and angiogenesis inhibitors. ImClone Systems' headquarters and research operations are set in New York City, with extra administration and manufacturing facilities in Branchburg, New Jersey. For more information more or less ImClone Systems, please visit the Company's web site at hTTP://www.imclone.com.
Certain matters discussed in this news release may plant forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the company believes that the expectations reflected in such advanced statements ar based upon reasonable assumptions, it can buoy give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could causal agency actual results to differ materially from those projecting. Many of these factors are beyond the company's ability to control or predict. Important factors that may cause actual results to differ materially and could wallop the company and the statements contained in this news waiver can be found in the company's filings with the Securities and Exchange Commission, including quarterly reports on Form 10-Q, current reports on Form 8-K and yearly reports on Form 10-K. For advanced statements in this news program release, the company claims the protection of the safe hold for modern statements contained in the Private Securities Litigation Reform Act of 1995. The company assumes no obligation to update or supplementation any modern statements whether as a result of new information, future events or otherwise.
ImClone Systems
More info
Tuesday 9 September 2008
Saturday 30 August 2008
Day Watch
We palpate the pull of the metaphorical clear and sinister everyday: Should I lie down? Steal? Cheat? Have that second sports stadium of ice cream? Or should I do the "right" thing? Taking this push-pull of desires and ideals and applying it to the supernatural is the crux Australis of Day Watch, the irregular film in the Night Watch series. Unfortunately, like its predecessor, Day Watch gets caught up in its flashy, sinful visual personal effects and misses the thematic mark. But that's what you'd expect from whatsoever other vainglorious budget "blockbuster."
As follow-up to the outset major button of a Russian picture after the collapse of the Soviet film manufacture (Night Watch had a budget of $4.2 million), Day Watch does an admirable job of keeping the pace snappy and the action constant, despite the fact that the plastic film is built upon unconvincing plot devices. The film follows Night Watch protagonist Anton as he attempts to reconnect with his son Yegor, who defected to the dark side, while pursuing a relationship with a new trainee in the Night Watch -- a group that polices the dark occult beings (the dark police force keeping tabs on the light face is the Day Watch).
The film makes no attempts to veil its subtext, Yegor is the Great Dark One and Anton's love interest is the Great Light One; both of them literally pull for his attention from either side. And the MacGuffin driving the action? The Chalk of Fate -- a magical piece of chalk that can change events depending on what the holder writes. Best not even to mention the 30 transactions Anton spends as a woman and bunks with his enamored trainee, in a inexpensive, manipulative way to drive the love story frontward as quickly as possible.
In an ironic twist, the saving gracility of Day Watch is also what takes away from the film's tarradiddle -- the visual personal effects. It's non that the effects are particularly good, but conductor Timur Bekmambetov has a visual style that's unitary part Jean-Pierre Jeunet (City of Lost Children, Amelie) and one part Wachowski brothers (The Matrix, Speed Racer). For the most part, it works for him: Day Watch's action keeps the film ploughing through the nagging patch questions of "Who's that again?" and "What's natural event?" Perhaps the most discrete and interesting use of effects is the visual punctuations within the subtitles: "Bitch!" splatters in red against a white wall as a hurled ball of raw meat slides down it; words aforementioned in ire violently shake and shatter, while utterances of despair dissolve into vapor. The visual caption twist works well for the action-driven film where eye candy is more important than genuine emotion, and it may even curb cries of ennui from lazy moviegoers world Health Organization don't need to "translate" their movies.
Although Day Watch is the Russian equivalent of a Hollywood money-grabber, it's astonishingly fun and at least gives the illusion of depth with Anton's pining over his dark son. Entering a genre that's overstuffed with bombastic computer-generated effects, Day Watch's supernatural police and Bekmambetov's rich visual palette give the film enough strength at least to throw a couple elbows to put itself apart from other nameless films with flock of personal effects, but small vision.
Aka Dnevnoy dozor.
Yep, it's Memorex.
Wednesday 20 August 2008
Nanotubes Deliver High-potency Punch To Cancer Tumors In Mice By Slipping Through Cell Walls
�The trouble with victimization a shotgun to kill a housefly is that even if you catch the pesterer, you'll likely do a lot of damage to your home in the process. Hence the value of the more surgical flyswatter.
Cancer researchers have long faced a alike situation in chemotherapy: how to make the to the highest degree medication into the cells of a tumor without "spillover" of the medicinal drug adversely affecting the healthy cells in a patient's body.
Now researchers at Stanford University have addressed that problem using single-walled carbon nanotubes as rescue vehicles. The new method has enabled the researchers to pose a higher proportion of a given dose of medication into the tumor cells than is possible with the "free" do drugs - that is, the one non bound to nanotubes - thus reducing the amount of medication that they need to inject into a subject to achieve the desired therapeutic effect.
"That means you testament also give less drug reaching the normal tissue," said Hongjie Dai, professor of chemical science and senior author of a newspaper, which testament be published in the Aug. 15 issue of Cancer Research. So not only is the medication more effective against the tumor, troy ounce for oz., but it greatly reduces the side effects of the medicinal drug.
Graduate student Zhuang Liu is first-class honours degree author of the paper.
Dai and his colleagues worked with paclitaxel, a widely used cancer chemotherapy drug, which they employed against tumors cells of a type of breast cancer that were ingrained under the skin of mice. They found that they were able to get up to 10 times as much medication into the tumor cells via the nanotubes as when the standard formulation of the drug, called Taxol�, was injected into the mice.
The neoplasm cells were allowed to proliferate for about iI weeks prior to beingness treated. After 22 days of treatment, tumors in the mice treated with the paclitaxel-bearing nanotubes were on average less than half the size of those in mice treated with Taxol.
Critical to achieving those results were the size and surface structure of the nanotubes, which governed how they interacted with the walls of the blood vessels through which they circulated after organism injected. Though a tattling vessel - nautical or anatomical - is rarely a good thing, in this illustration the comparatively leaky walls of profligate vessels in the neoplasm tissue provided the opening that the nanotubes requisite to pillowcase into the tumor cells.
"The results are actually highly dependent on the surface chemical science," Dai said. "In other words, you don't get this final result just by attaching drugs to any nanotubes."
The researchers secondhand nanotubes that they had coated with polyethylene glycol (PEG), a common ingredient in cosmetics. The PEG they used was a form that has leash little branches sprouting from a primal trunk. Stuffing the trunks into the linked hexangular rings that make up the nanotubes created a visual gist that Dai described as looking like rolled-up chicken wire with feathers projecting out all over. The homespun sounding appearance notwithstanding, the nanotubes proved to be highly effective delivery vehicles when the researchers attached the paclitaxel to the tips of the branches.
Dai's team has found in earlier work (Proceedings of the National Academy of Sciences, Vol. 105, No. 5, 1410-1415, Feb. 5, 2008) that coating nanotubes with PEG was an effective way to keep the nanotubes circulating in the bloodstream for up to 10 hours, long enough to find their way to the fair game location and much yearner than give up medication would circulate. Although attaching the paclitaxel to the PEG turned out to slim down the circulation time, it proved to still be long sufficiency to deliver a highly effective dose inside the tumor cells.
All blood vessel walls are somewhat porous, just in intelligent vessels the pores are relatively small. By tinkering with the length of the nanotubes, the researchers were able to orient the nanotubes so that they were too large to get through the holes in the walls of normal blood vessels, but still small sufficiency to easily slip through the larger holes in the relatively leaky rake vessels in the tumor tissue.
That enabled the nanotubes to deliver their medicinal loading with tremendous efficiency, throwing a therapeutic wrench into the cellular means of reproduction and thus squelching the until now unrestrained proliferation of the tumor cells.
Dai aforementioned that the technique holds potential for delivering a range of medications and that it may as well be possible to grow ways to channel the nanotubes to their target even more precisely.
"Right now what we ar doing is so-called 'passive targeting,' which is using the leaky vasculature of the tumor," he said. "But a more than active targeting would be attaching a peptide or antibody to the carbon nanotube drug, matchless that will bind more specifically to the tumor, which should further enhance the treatment efficacy."
Dai's team is already at work development more targeted approaches, and he is optimistic about the electric potential applications of nanotubes.
"We are emphatically hoping to be able to push this to practical applications into the clinic. This is one step onward," he said. "But it will still take time to sincerely prove the efficacy and the safety."
The work was funded by the NIH-National Cancer Institute Center for Cancer Nanotechnology Excellence Focused on Therapeutic Response at Stanford, a Stanford Bio-X Initiative Grant, NIH-National Cancer Institute Grant and a Stanford Graduate Fellowship. Collaborators on this work included Assistant Professor Shawn Chen's grouping in the Stanford Department of Radiology.
-- Link to paper in Cancer Research
-- Link to February PNAS theme
Source - Louis Bergeron
Stanford University
View drug information on Taxol.
More info
Cancer researchers have long faced a alike situation in chemotherapy: how to make the to the highest degree medication into the cells of a tumor without "spillover" of the medicinal drug adversely affecting the healthy cells in a patient's body.
Now researchers at Stanford University have addressed that problem using single-walled carbon nanotubes as rescue vehicles. The new method has enabled the researchers to pose a higher proportion of a given dose of medication into the tumor cells than is possible with the "free" do drugs - that is, the one non bound to nanotubes - thus reducing the amount of medication that they need to inject into a subject to achieve the desired therapeutic effect.
"That means you testament also give less drug reaching the normal tissue," said Hongjie Dai, professor of chemical science and senior author of a newspaper, which testament be published in the Aug. 15 issue of Cancer Research. So not only is the medication more effective against the tumor, troy ounce for oz., but it greatly reduces the side effects of the medicinal drug.
Graduate student Zhuang Liu is first-class honours degree author of the paper.
Dai and his colleagues worked with paclitaxel, a widely used cancer chemotherapy drug, which they employed against tumors cells of a type of breast cancer that were ingrained under the skin of mice. They found that they were able to get up to 10 times as much medication into the tumor cells via the nanotubes as when the standard formulation of the drug, called Taxol�, was injected into the mice.
The neoplasm cells were allowed to proliferate for about iI weeks prior to beingness treated. After 22 days of treatment, tumors in the mice treated with the paclitaxel-bearing nanotubes were on average less than half the size of those in mice treated with Taxol.
Critical to achieving those results were the size and surface structure of the nanotubes, which governed how they interacted with the walls of the blood vessels through which they circulated after organism injected. Though a tattling vessel - nautical or anatomical - is rarely a good thing, in this illustration the comparatively leaky walls of profligate vessels in the neoplasm tissue provided the opening that the nanotubes requisite to pillowcase into the tumor cells.
"The results are actually highly dependent on the surface chemical science," Dai said. "In other words, you don't get this final result just by attaching drugs to any nanotubes."
The researchers secondhand nanotubes that they had coated with polyethylene glycol (PEG), a common ingredient in cosmetics. The PEG they used was a form that has leash little branches sprouting from a primal trunk. Stuffing the trunks into the linked hexangular rings that make up the nanotubes created a visual gist that Dai described as looking like rolled-up chicken wire with feathers projecting out all over. The homespun sounding appearance notwithstanding, the nanotubes proved to be highly effective delivery vehicles when the researchers attached the paclitaxel to the tips of the branches.
Dai's team has found in earlier work (Proceedings of the National Academy of Sciences, Vol. 105, No. 5, 1410-1415, Feb. 5, 2008) that coating nanotubes with PEG was an effective way to keep the nanotubes circulating in the bloodstream for up to 10 hours, long enough to find their way to the fair game location and much yearner than give up medication would circulate. Although attaching the paclitaxel to the PEG turned out to slim down the circulation time, it proved to still be long sufficiency to deliver a highly effective dose inside the tumor cells.
All blood vessel walls are somewhat porous, just in intelligent vessels the pores are relatively small. By tinkering with the length of the nanotubes, the researchers were able to orient the nanotubes so that they were too large to get through the holes in the walls of normal blood vessels, but still small sufficiency to easily slip through the larger holes in the relatively leaky rake vessels in the tumor tissue.
That enabled the nanotubes to deliver their medicinal loading with tremendous efficiency, throwing a therapeutic wrench into the cellular means of reproduction and thus squelching the until now unrestrained proliferation of the tumor cells.
Dai aforementioned that the technique holds potential for delivering a range of medications and that it may as well be possible to grow ways to channel the nanotubes to their target even more precisely.
"Right now what we ar doing is so-called 'passive targeting,' which is using the leaky vasculature of the tumor," he said. "But a more than active targeting would be attaching a peptide or antibody to the carbon nanotube drug, matchless that will bind more specifically to the tumor, which should further enhance the treatment efficacy."
Dai's team is already at work development more targeted approaches, and he is optimistic about the electric potential applications of nanotubes.
"We are emphatically hoping to be able to push this to practical applications into the clinic. This is one step onward," he said. "But it will still take time to sincerely prove the efficacy and the safety."
The work was funded by the NIH-National Cancer Institute Center for Cancer Nanotechnology Excellence Focused on Therapeutic Response at Stanford, a Stanford Bio-X Initiative Grant, NIH-National Cancer Institute Grant and a Stanford Graduate Fellowship. Collaborators on this work included Assistant Professor Shawn Chen's grouping in the Stanford Department of Radiology.
-- Link to paper in Cancer Research
-- Link to February PNAS theme
Source - Louis Bergeron
Stanford University
View drug information on Taxol.
More info
Sunday 10 August 2008
Sara Bareilles
Artist: Sara Bareilles
Genre(s):
Rock
Discography:
Little Voice
Year: 2007
Tracks: 12
Careful Confessions
Year:
Tracks: 11
As a gifted singer and a versatile pianoforte player with no courtly breeding, Sara Bareilles burst onto the pop fit with a by nature skilled voice ranging from knock-down and soulful to sweet and soft, earning her instantaneous comparisons to Fiona Apple and Norah Jones. At eld 18, she left field the Redwood forests of her hometown, Eureka, CA, in interest of the big city lights of Los Angeles. Although she attended UCLA's Communication Studies programme, Bareilles spent the bulk of her spare time perusing her new surroundings and piece of writing poetry and songs around the busy environs. After graduating, she dog-tired the future trey days playing those songs at open-mike nights, slowly building her trust as a instrumentalist before playing local venues and festivals. In 2003, she co-produced her first base demonstration, Careful Confessions, and became charmed with recording techniques. Eager to go back to the studio and make a second gear full-length album, she started shopping her CD round and signed a sell with Epic Records in April 2005. Producer Eric Rosse took her under his wing the following February and the deuce exhausted a short over a year perfecting the orchestration -- about half of the songs had once appeared on Careful Confessions and a modern batch of tracks was carefully constructed in parliamentary jurisprudence to make her first-class honours degree major-label release as strong as possible. The lyric themes of the album, entitled Minuscule Voice and released in July 2007, covered her past relationships, insecurities, and inner battles with trying to trust her instincts.
Exos
Tuesday 1 July 2008
Peter Hammill
Artist: Peter Hammill
Genre(s):
Rock
ROck: Alternative
Other
Rock: Electronic
Discography:
Spur of the Moment
Year: 2005
Tracks: 11
Incoherence
Year: 2005
Tracks: 1
This
Year: 2003
Tracks: 10
What, Now?
Year: 2001
Tracks: 8
None of the Above
Year: 2000
Tracks: 8
Sonix
Year: 1997
Tracks: 9
Everyone You Hold
Year: 1997
Tracks: 9
X My Heart
Year: 1996
Tracks: 9
Roaring Forties
Year: 1994
Tracks: 13
The Noise - There goes The daylight
Year: 1993
Tracks: 10
The Noise
Year: 1993
Tracks: 8
Offensichtlich Goldfisch
Year: 1993
Tracks: 12
The Fix on the Mix
Year: 1992
Tracks: 4
Nadir's Big Chance
Year: 1992
Tracks: 11
Fireships
Year: 1992
Tracks: 9
A Fix On The Mix
Year: 1992
Tracks: 4
The Fall of the House of Usher
Year: 1991
Tracks: 21
The Silent Corner and The Empty Stage
Year: 1990
Tracks: 7
Out of Water
Year: 1990
Tracks: 8
Chameleon in the Shadow of the Night
Year: 1990
Tracks: 8
In a Foreign Town
Year: 1988
Tracks: 12
Skin
Year: 1986
Tracks: 8
And Close As This
Year: 1986
Tracks: 8
The Love Songs
Year: 1984
Tracks: 10
Love Songs
Year: 1984
Tracks: 10
Patience
Year: 1983
Tracks: 8
Loops and Reels
Year: 1983
Tracks: 7
Black Box
Year: 1983
Tracks: 8
Enter K
Year: 1982
Tracks: 8
Sitting Targets
Year: 1981
Tracks: 11
Sitting Targes
Year: 1981
Tracks: 11
A Black Box
Year: 1980
Tracks: 8
Ph7
Year: 1979
Tracks: 11
Ph 7
Year: 1979
Tracks: 11
The Future Now
Year: 1978
Tracks: 12
Future Now
Year: 1978
Tracks: 12
Over
Year: 1977
Tracks: 8
The Silent Corner and The Empty
Year: 1974
Tracks: 7
In Camera
Year: 1974
Tracks: 7
Chameleon In The Shadow Of The
Year: 1973
Tracks: 8
Chameleon In The Shadow Of Night
Year: 1973
Tracks: 8
Fools Mate
Year: 1971
Tracks: 12
Thin Man Sings Ballads
Year:
Tracks: 12
Born Peter Joseph Andrew Hammill, November 5, 1948, in Ealing, London, to parents of clean good means, Peter Hammill grew up in the embrace of the Jesuit faith, an element that has continued to affect and influence his songwriting throughout his career as a lot as his studies of philosophy and fine art. The drive of his particular muse, fueled to boot by the '60s groundswell of new approaches to skill fabrication (the so-called "New Wave," with Michael Moorcock, Thomas Disch, Harlan Ellison, and others leading the consign, and ex-Deviants drawing card Mick Farren on its heels) light-emitting diode to collaboration with Chris Judge-Smith at Manchester University, with Van Der Graaf Generator forming around them -- albeit briefly.
The band skint up afterward a figure of gigs, with Hammill going solo. The comer of a Mercury Records contract light-emitting diode Hammill into the studio, accompanied by versatile friends, for a abbreviated but vivid recording academic session. Within a matter of hours, Van Der Graaf Generator was reborn, though minus Judge-Smith, and the band had begun to develop the studio relationship with producer John Anthony that would serve them for the succeeding few albums. The canonical monumental VDGG had not still come about, but Hammill's writing was already place setting the note -- splintered personalities facing the darkness, cosmic secrets just beyond strive, thresholds beyond which skulk sudden decease, lighthearted topics one and all. Even their one individual, "People You Were Going To," is basically a jolly glad play of a tune with a musical note of despair at a lower place. Hammill would afterward re-record the song for Nadir's Big Chance.
The new band lineup had its possess percentage of uncertainties, with bassist Keith Ellis departing for an unceremoniously brief stint in Uriah Heep. With new bassist/guitarist Nic Potter in towage, VDGG united Genesis in signing with Anthony Stratton-Smith's new Charisma label. By this power point Hammill had begun to down his songwriting into thirster and more flowery forms, with very good results, with his themes touch on twin points of skill and mysticism, with the occasional sidestep into more downward to earth territory. The number one trey VDGG albums for Charisma touched through a variety of shattered and darkened landscapes, with some authentically temperature reduction moments, such as the science fiction junket "Pioneers Over C" and "Man-Erg," which attempted to address the dual nature of man in around 12 transactions flat.
Hammill's number 1 solo junket, Fool's Mate (both a cheat and Tarot reference), came aboard the Van Der Graaf Generator record album H to He Who Am the Only One. It consisted, in the principal, of an mixed bag of songs deemed to a fault small for the ring, real from his early solo days, and so on, items that he seemed to want to clear forbidden of the elbow room. His in-studio help included members of Lindisfarne, some other Charisma signing, and Robert Fripp. In direct contrast, following the licentiousness of VDGG undermentioned Pawn Hearts, Hammill's soph release, The Chameleon in the Shadow of the Night, was a black affair indeed. Hammill seemed to demand to denude things depressed to the nude essentials, recording at base (the number one appearance of Sofa Sound) for the to the highest degree component part, his lyrics telling more personal tales -- it's only if with the last "The Black Room" that things sound conversant. Considering the presence of the rest of the band, and that this had in the first place been intended as a banding song, it's hardly a surprise.
With The Silent Corner and the Empty Stage, Hammill began to bump a voice away from VDGG, though his written material had still to completely age -- "Red River Shift" is some other cosmic burden, for exercise. On the other hand, the album sports several arresting tracks, including "Modern," "Wilhelmina," "Forsaken Gardens," and "A Louse Is Not a Home." In Camera byword him handling virtually of the subservient work himself and experimenting with ambient soundscapes.
In 1975, he once once again dug into the back catalog of his songs, assuming the leather-jacketed image of Rikki Nadir for Nadir's Big Chance, a noisy, chaotic album of garage band-styled stone & wrap. While non exactly the three-chord thrash picnic Hammill seems to get wanted (it at least comes done for with the elegaic "Pompeii," if non with "The Institute of Mental Health, Burning"), the record album seems to have had its effect in the British music community, existence cited by more than a few in the next toughie tumultuousness as an influence -- even John Lydon went populace with a degree of admiration for Hammill's work. The cult of worship built up round Hammill has persisted for age, and is on the face of it orotund sufficiency, worldwide, to support him systematically.
1975 adage the reincarnation of Van Der Graaf Generator in a reasonably calmer format, patch the songs still extended to epic length, the trend towards proto-jazz explosions with rock and roll underpinnings had been shorn away, the drumming was more laid back, and the lyrics tended towards examinations of masses (though the cosmic did make quite a return on Still Life with "Round-eyed Faith in Childhood's End," though this one had a tale voice to it).
The first base iI releases, Godbluff and Inactive Life, were fine albums, with one of Hammill's finest songs, "My Room (Wait for Wonderland)" appearing on the latter, only the third album, World Record indicated fuss ahead -- a passably weak, lifeless release that appeared to take come from a band that had lost heart. Indeed it had. The band fractured yet over again. Hammill took some time to record Over, an intense solo set going over the detachment of his longstanding relationship, acting a set of songs that alternately raged and offered up a cutting view of living. This fix the stage for the next version of the banding, now known simply as Van Der Graaf, a transitory exploit that managed a single studio press release, with a posthumous live album, acidly coroneted Life-sustaining, marking the official death of the band.
Hammill returned to his solo efforts once again, ab initio choosing to track record A Black Box by himself, just then adopting a band approach for a issue of subsequent releases. By this point his writing had taken on a mature focus, with even the lengthier efforts eschewing the cosmic and mystical in favour of the personal focus, often with a darkly dry construction. He is capable of existence dead sardonic while maintaining a fire hook face, a brother in intent, sometimes, to Leonard Cohen. His ability to chart his own trend to the full stems from his option to engage his own record label as an adjunct to his ever-improving studio operation -- it's this studio apartment operation, in fact, that allowed him to return to and remaster the Van Der Graaf recordings in 2000, to grow The Box.
A unconstipated output of new recordings is supported by an ongoing series of concert appearances around the world, as well as numerous collaborations with a bewildering variety of artists -- Roger Eno, Peter Gabriel, and Robert Fripp are scarcely trio of stacks. Hammill has also composed concert dance music, and the operatic exploit, The Fall of the House of Usher (based on the Edgar Allan Poe story). He has been matrimonial for quite an some time and has trey daughters, iI of whom take made appearances on his albums. Despite his selfsame world part, however, he cadaver a slightly enigmatical and private man whose music confounds some and inspires many.
mp3 music download
Monday 9 June 2008
Bond - Arterton Dating Kebbell
BOND girl GEMMA ARTERTON is reportedly dating her ROCKNROLLA co-star TOBY KEBBELL - after the pair fell for each other while filming the movie.
The British actress allegedly fell for the 25-year-old Alexander star's charms while working on the latest gangster movie by Madonna's husband Guy Ritchie.
And the pair don't have to worry about their hectic movie schedules ruining their romance - they are set to appear opposite each other in forthcoming blockbuster Prince Of Persia, scheduled to be shot later this year (08) in Egypt.
A source tells Britain's Mail On Sunday, "Romance is on the cards. They hit it off when they were making RocknRolla and fell for each other on set."
See Also
Tuesday 3 June 2008
Britney Spears - The Things They Say 8344
"(He) makes me sick. His earlobes are stretched out from all the diamonds he stole from BRITNEY SPEARS. He's a pig and a loser and I want to take him down." Acid-tongued former supermodel JANICE DICKINSON also has some choice words for BRITNEY SPEARS' ex husband KEVIN FEDERLINE.
See Also
Subscribe to:
Posts (Atom)